Banner image placeholder
Banner image
Site avatar

Linda My Huynh

MD/PhD Scholar

Diagnostic performance of a novel radiomic model for predicting post-treatment prostate cancer recurrence: A comparison to CAPRA and MSKCC nomograms.


Journal article


L. Huynh, Olivia Taylor, Jacob T Marasco, Shuo Wang, M. Baine
JCO Global Oncology, 2023

Semantic Scholar DOI
Cite

Cite

APA   Click to copy
Huynh, L., Taylor, O., Marasco, J. T., Wang, S., & Baine, M. (2023). Diagnostic performance of a novel radiomic model for predicting post-treatment prostate cancer recurrence: A comparison to CAPRA and MSKCC nomograms. JCO Global Oncology.


Chicago/Turabian   Click to copy
Huynh, L., Olivia Taylor, Jacob T Marasco, Shuo Wang, and M. Baine. “Diagnostic Performance of a Novel Radiomic Model for Predicting Post-Treatment Prostate Cancer Recurrence: A Comparison to CAPRA and MSKCC Nomograms.” JCO Global Oncology (2023).


MLA   Click to copy
Huynh, L., et al. “Diagnostic Performance of a Novel Radiomic Model for Predicting Post-Treatment Prostate Cancer Recurrence: A Comparison to CAPRA and MSKCC Nomograms.” JCO Global Oncology, 2023.


BibTeX   Click to copy

@article{l2023a,
  title = {Diagnostic performance of a novel radiomic model for predicting post-treatment prostate cancer recurrence: A comparison to CAPRA and MSKCC nomograms.},
  year = {2023},
  journal = {JCO Global Oncology},
  author = {Huynh, L. and Taylor, Olivia and Marasco, Jacob T and Wang, Shuo and Baine, M.}
}

Abstract

76 Background: mpMRI-derived radiomic features have been shown to capture sub-visual patterns for quantitative characterization of tumor phenotype. We seek to compare the diagnostic performance of a mpMRI-based radiomic model to currently available nomograms for prediction of post-radical prostatectomy (RP) biochemical recurrence (BCR). Methods: mpMRI was obtained from 76 patients who had underwent RP for treatment of localized PCa. All patients had ≥2 years follow-up and those with neo-adjuvant or adjuvant treatment were excluded. Radiomic analysis and cross-validation of mpMRI features yielded features significantly correlated with BCR, defined as two consecutive serum PSA≥0.2ng/ml. These features were aggregated to construct a radiomic model, which was compared to the risk scores generated by inputting patients’ clinicodemographic features into the USCF Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score and Memorial Sloan Kettering Cancer Center (MSKCC) Pre-Radical Prostatectomy nomogram. The performance of each model was compared utilizing receiver-operator curve (ROC) analysis and area under the curve (AUC) was reported. Results: In feature extraction and ranking, six radiomic features were determined to be important and non-redundant in predicting PCa recurrence (least material condition, gray-level non-uniformity, shape-elongation, shape-sphericity, first-order skewness). These features were aggregated into the radiomic model and repeated five-fold cross validation yielded a model with AUC of 0.95±0.06, 33% sensitivity, and 100% specificity. UCSF-CAPRA and MSKCC nomograms yielded AUC of 0.72±0.07 and 0.82±0.07, respectively. Conclusions: The mpMRI-derived radiomic model performed well when compared to the UCSF-CAPRA score and MSKCC Pre-Radical Prostatectomy nomogram. Future projects will incorporate patient demographics and disease characteristics available at the time of initial PCa diagnosis to improve the radiomic model accuracy.


Share

Text Only Owlstown
QR Code
Translate to